SK155997A3 - Use of ribavirin and interferon alpha for the treatment of hepatitis c - Google Patents
Use of ribavirin and interferon alpha for the treatment of hepatitis c Download PDFInfo
- Publication number
- SK155997A3 SK155997A3 SK1559-97A SK155997A SK155997A3 SK 155997 A3 SK155997 A3 SK 155997A3 SK 155997 A SK155997 A SK 155997A SK 155997 A3 SK155997 A3 SK 155997A3
- Authority
- SK
- Slovakia
- Prior art keywords
- ribavirin
- interferon alpha
- hepatitis
- interferon
- amount
- Prior art date
Links
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 title claims abstract description 24
- 229960000329 ribavirin Drugs 0.000 title claims abstract description 24
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 title claims abstract description 24
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 22
- 102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 22
- 208000006454 hepatitis Diseases 0.000 title description 2
- 231100000283 hepatitis Toxicity 0.000 title 1
- 230000001684 chronic effect Effects 0.000 claims description 12
- 208000037319 Hepatitis infectious Diseases 0.000 claims description 10
- 208000005252 hepatitis A Diseases 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 3
- 102100040018 Interferon alpha-2 Human genes 0.000 claims description 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims description 2
- 206010062237 Renal impairment Diseases 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 230000003442 weekly effect Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 15
- 208000020403 chronic hepatitis C virus infection Diseases 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 102000014150 Interferons Human genes 0.000 description 12
- 108010050904 Interferons Proteins 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 11
- 229940079322 interferon Drugs 0.000 description 9
- 238000009097 single-agent therapy Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 7
- 238000002648 combination therapy Methods 0.000 description 6
- 108010078049 Interferon alpha-2 Proteins 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 208000005176 Hepatitis C Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 3
- 229940047124 interferons Drugs 0.000 description 3
- 206010022004 Influenza like illness Diseases 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 229960003507 interferon alfa-2b Drugs 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- MIXCUJKCXRNYFM-UHFFFAOYSA-M sodium;diiodomethanesulfonate;n-propyl-n-[2-(2,4,6-trichlorophenoxy)ethyl]imidazole-1-carboxamide Chemical compound [Na+].[O-]S(=O)(=O)C(I)I.C1=CN=CN1C(=O)N(CCC)CCOC1=C(Cl)C=C(Cl)C=C1Cl MIXCUJKCXRNYFM-UHFFFAOYSA-M 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000006154 Chronic hepatitis C Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019837 Hepatocellular injury Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000007397 Species specific proteins Human genes 0.000 description 1
- 108020005719 Species specific proteins Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 108010055511 interferon alfa-2c Proteins 0.000 description 1
- 108010006088 interferon alfa-n1 Proteins 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- -1 transdermal Substances 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/212—IFN-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/444,584 US6387365B1 (en) | 1995-05-19 | 1995-05-19 | Combination therapy for chronic hepatitis C infection |
| PCT/US1996/006552 WO1996036351A1 (en) | 1995-05-19 | 1996-05-15 | Use of ribavirin and interferon alpha for the treatment of hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK155997A3 true SK155997A3 (en) | 1998-10-07 |
Family
ID=23765515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1559-97A SK155997A3 (en) | 1995-05-19 | 1996-05-15 | Use of ribavirin and interferon alpha for the treatment of hepatitis c |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US6387365B1 (pt) |
| EP (2) | EP1005868A1 (pt) |
| JP (1) | JPH10506640A (pt) |
| KR (1) | KR19990014925A (pt) |
| CN (1) | CN1190895A (pt) |
| AU (1) | AU5919296A (pt) |
| BR (1) | BR9608758A (pt) |
| CA (1) | CA2221314A1 (pt) |
| CZ (1) | CZ365497A3 (pt) |
| HU (1) | HUP9802324A3 (pt) |
| NO (1) | NO975309D0 (pt) |
| NZ (1) | NZ309217A (pt) |
| PL (1) | PL323477A1 (pt) |
| SK (1) | SK155997A3 (pt) |
| WO (1) | WO1996036351A1 (pt) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) * | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| CA2329474C (en) | 1995-11-02 | 2002-02-26 | Schering Corporation | Continuous low-dose cytokine infusion therapy |
| JP3416147B2 (ja) * | 1996-01-23 | 2003-06-16 | アイ・シー・エヌ・フアーマシユーテイカルズ・インコーポレイテツド | 活性化ｔリンパ球におけるリバビリン及びリバビリン類似体によるｔｈ１型／ｔｈ２型サイトカインの発現の調節 |
| DE69712316T2 (de) * | 1996-01-23 | 2003-01-02 | Icn Pharmaceuticals, Inc. | Modulation der th1/th2 cytokinexpression durch ribavirin in aktivierten t-lymphozyten |
| US20020137696A1 (en) * | 1996-01-23 | 2002-09-26 | Robert Tam | Specific modulation of TH1/TH2 cytokine expression by ribavirin in activated T-lymphocytes |
| DK0886527T3 (da) * | 1996-02-28 | 2002-03-04 | Unihart Corp | Farmaceutiske sammensætninger indeholdende naturligt humant alfa-interferon |
| WO1998019670A2 (en) * | 1996-11-01 | 1998-05-14 | Thomas Najarian | Combination therapy of hepatitis c infections |
| US6172046B1 (en) * | 1997-09-21 | 2001-01-09 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
| US6472373B1 (en) | 1997-09-21 | 2002-10-29 | Schering Corporation | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
| DK0903148T3 (da) * | 1997-09-21 | 2001-12-17 | Schering Corp | Kombinationsterapi til udryddelse af påviselig HCV-RNA hos patienter med kronisk hepatitis C infektion |
| ZA9811726B (en) * | 1997-12-22 | 1999-06-21 | Schering Corp | Orally administrable solid ribavirin dosage forms and process for making them |
| SK288038B6 (en) * | 1998-05-15 | 2013-01-02 | Merck Sharp & Dohme | Use of ribavirin and interferon alpha for manufacture pharmaceutical compositions for treating chronic hepatitis C infection |
| KR20050055053A (ko) * | 1998-06-08 | 2005-06-10 | 에프. 호프만-라 로슈 아게 | 만성 Ｃ형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-α 및 리바비린의 용도 |
| EP1109580A4 (en) * | 1998-09-04 | 2004-05-26 | Viropharma Inc | METHOD FOR TREATING OR PREVENTING VIRAL INFECTIONS AND RELATED DISEASES |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
| BR9915546A (pt) * | 1998-10-16 | 2001-08-14 | Schering Corp | Terapia de combinação de ribavirin- interferon alfa para a erradiação de hcv-rna detectável em pacientes tendo infecção por hepatite c crÈnica |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| AU2156900A (en) * | 1998-12-18 | 2000-07-12 | Schering Corporation | Ribavirin-interferon alfa induction hcv combination therapy |
| EP1140143A2 (en) * | 1998-12-18 | 2001-10-10 | Schering Corporation | Ribavirin-pegylated interferon alfa induction hcv combination therapy |
| US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
| NZ517634A (en) * | 1999-12-23 | 2004-06-25 | Icn Pharmaceuticals | Compositions and methods for L-nucleosides, L-nucleotides, and their analogs |
| ES2529300T3 (es) | 2000-04-12 | 2015-02-18 | Novozymes Biopharma Dk A/S | Proteínas de fusión de albúmina |
| US6924270B2 (en) * | 2000-04-20 | 2005-08-02 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| CZ2003311A3 (cs) * | 2000-08-02 | 2004-04-14 | Ortho-Mcneil Pharmaceutical, Inc. | Protivirová a protinádorová terapie za použití erythropoetinu |
| US20060024270A1 (en) * | 2000-08-23 | 2006-02-02 | The New York Hospital Medical Center Of Queens | Compositions and methods for preventing or treating encephalitis with interferon |
| US6946125B2 (en) * | 2000-08-23 | 2005-09-20 | The New York Hospital Medical Center Of Queens | Methods of treating West Nile virus infection |
| WO2002032414A2 (en) * | 2000-10-18 | 2002-04-25 | Schering Corporation | Ribavirin-pegylated interferon alfa hcv combination therapy |
| US6720000B2 (en) | 2001-03-19 | 2004-04-13 | Three Rivers Pharmaceutical, Llc | Process for producing wet ribavirin pellets |
| EP1401477A4 (en) * | 2001-05-25 | 2005-02-02 | Human Genome Sciences | CHIMIOKINE BETA-1 HYBRID PROTEINS |
| AU2002346686A1 (en) * | 2001-12-07 | 2003-06-23 | Intermune, Inc. | Compositions and method for treating hepatitis virus infection |
| KR101271635B1 (ko) * | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| ES2425738T3 (es) * | 2001-12-21 | 2013-10-17 | Human Genome Sciences, Inc. | Proteínas de fusión de la albúmina |
| WO2004004653A2 (en) * | 2002-07-02 | 2004-01-15 | Corcept Therapeutics, Inc. | Methods for treating psychosis associated with interferon-alpha therapy |
| WO2004022593A2 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| US7538094B2 (en) | 2002-09-19 | 2009-05-26 | Three Rivers Pharmacueticals, Llc | Composition containing ribavirin and use thereof |
| JP2004143113A (ja) * | 2002-10-25 | 2004-05-20 | Shinya Nakajima | インターフェロン製剤及びその投与システム |
| CA2513213C (en) | 2003-01-22 | 2013-07-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| GB0301879D0 (en) * | 2003-01-27 | 2003-02-26 | Regent Res Llp | HCV combination therapy |
| MXPA05010419A (es) * | 2003-03-28 | 2006-05-31 | Pharmasset Inc | Compuestos para el tratamiento de infecciones por flaviviridae. |
| TW200523270A (en) | 2003-07-18 | 2005-07-16 | Vertex Pharma | Inhibitors of serine proteases, particularly HCV ns3-ns4a protease |
| JPWO2006033453A1 (ja) * | 2004-09-22 | 2008-05-15 | 学校法人順天堂 | インターフェロン作用物質の活性増強剤 |
| US7723310B2 (en) | 2004-10-18 | 2010-05-25 | Three Rivers Pharmaceuticals, Llc | Large dose ribavirin formulations |
| EP1850862A2 (en) * | 2005-01-19 | 2007-11-07 | Avigenics, Inc. | Methods of treating disease with glycosylated interferon |
| JP5034944B2 (ja) * | 2005-07-27 | 2012-09-26 | 味の素株式会社 | インターフェロン作用物質の活性増強剤 |
| EP2356990A3 (en) | 2006-08-02 | 2011-10-19 | University of Oxford | Liposome treatment of viral infections |
| US20080131398A1 (en) * | 2006-08-21 | 2008-06-05 | United Therapeutics Corporation | Combination therapy for treatment of viral infections |
| US20080260820A1 (en) * | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| CN101820887A (zh) * | 2007-07-25 | 2010-09-01 | 拜奥雷克斯治疗公司 | 干扰素控释药品以及使用相同药品治疗hcv感染 |
| WO2009118658A2 (en) * | 2008-03-26 | 2009-10-01 | University Of Oxford | Endoplasmic reticulum targeting liposomes |
| PE20110343A1 (es) * | 2008-09-17 | 2011-06-25 | Boehringer Ingelheim Int | Combinacion de inhibidor de la proteasa ns3 de hcv con interferon y ribavirina |
| JP2012521981A (ja) * | 2009-03-27 | 2012-09-20 | ザ チャンセラー，マスターズ アンド スカラーズ オブ ザ ユニバーシティ オブ オックスフォード | コレステロールレベル低下リポソーム |
| EP2459211A1 (en) | 2009-07-31 | 2012-06-06 | Medtronic, Inc. | Continuous subcutaneous administration of interferon- to hepatitis c infected patients |
| US8822496B2 (en) | 2009-10-30 | 2014-09-02 | Boehringer Ingelheim International Gmbh | Dosage regimens for HCV combination therapy |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
| AR088463A1 (es) | 2011-10-21 | 2014-06-11 | Abbvie Inc | Metodos para el tratamiento de hcv |
| CN104436197A (zh) | 2011-10-21 | 2015-03-25 | 艾伯维公司 | 至少两种直接作用抗病毒剂的组合产品 |
| WO2013116592A1 (en) * | 2012-02-01 | 2013-08-08 | Kadmon Pharmaceuticals, Llc | Once daily treatment of hepatitis c with ribavirin and taribavirin |
| US11192914B2 (en) | 2016-04-28 | 2021-12-07 | Emory University | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4211771A (en) | 1971-06-01 | 1980-07-08 | Robins Ronald K | Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide |
| USRE29835E (en) | 1971-06-01 | 1978-11-14 | Icn Pharmaceuticals | 1,2,4-Triazole nucleosides |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US5676942A (en) * | 1992-02-10 | 1997-10-14 | Interferon Sciences, Inc. | Composition containing human alpha interferon species proteins and method for use thereof |
-
1995
- 1995-05-19 US US08/444,584 patent/US6387365B1/en not_active Expired - Lifetime
- 1995-12-28 EP EP99123925A patent/EP1005868A1/en not_active Withdrawn
- 1995-12-28 EP EP95309499A patent/EP0707855A3/en not_active Ceased
-
1996
- 1996-05-15 WO PCT/US1996/006552 patent/WO1996036351A1/en not_active Ceased
- 1996-05-15 PL PL96323477A patent/PL323477A1/xx unknown
- 1996-05-15 BR BR9608758A patent/BR9608758A/pt not_active Application Discontinuation
- 1996-05-15 CZ CZ973654A patent/CZ365497A3/cs unknown
- 1996-05-15 JP JP8534904A patent/JPH10506640A/ja active Pending
- 1996-05-15 CN CN96195591A patent/CN1190895A/zh active Pending
- 1996-05-15 NZ NZ309217A patent/NZ309217A/xx unknown
- 1996-05-15 SK SK1559-97A patent/SK155997A3/sk unknown
- 1996-05-15 KR KR1019970708271A patent/KR19990014925A/ko not_active Ceased
- 1996-05-15 AU AU59192/96A patent/AU5919296A/en not_active Abandoned
- 1996-05-15 CA CA002221314A patent/CA2221314A1/en not_active Abandoned
- 1996-05-15 HU HU9802324A patent/HUP9802324A3/hu unknown
-
1997
- 1997-11-19 NO NO975309A patent/NO975309D0/no not_active Application Discontinuation
-
2000
- 2000-05-02 US US09/563,649 patent/US6299872B1/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| AU5919296A (en) | 1996-11-29 |
| CN1190895A (zh) | 1998-08-19 |
| NZ309217A (en) | 2000-08-25 |
| WO1996036351A1 (en) | 1996-11-21 |
| CA2221314A1 (en) | 1996-11-21 |
| JPH10506640A (ja) | 1998-06-30 |
| EP1005868A1 (en) | 2000-06-07 |
| KR19990014925A (ko) | 1999-02-25 |
| US6299872B1 (en) | 2001-10-09 |
| EP0707855A2 (en) | 1996-04-24 |
| HUP9802324A3 (en) | 2001-04-28 |
| PL323477A1 (en) | 1998-03-30 |
| NO975309L (no) | 1997-11-19 |
| EP0707855A3 (en) | 1996-11-27 |
| HUP9802324A2 (hu) | 1999-05-28 |
| NO975309D0 (no) | 1997-11-19 |
| BR9608758A (pt) | 1999-07-06 |
| US6387365B1 (en) | 2002-05-14 |
| MX9708885A (es) | 1998-03-31 |
| CZ365497A3 (cs) | 1998-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SK155997A3 (en) | Use of ribavirin and interferon alpha for the treatment of hepatitis c | |
| US20050112093A1 (en) | Combination therapy for HCV infection | |
| KR20050055053A (ko) | 만성 Ｃ형 간염을 치료하기 위한 폴리에틸렌글리콜-인터페론-α 및 리바비린의 용도 | |
| US20070202078A1 (en) | Method Of Treating Viral Infections | |
| RU2002105485A (ru) | Применение микофенолята мофетила в сочетании с ПЭГ-интерфероном-α (ПЭГ-IFN-α) | |
| JP2007501806A5 (pt) | ||
| KR20140035305A (ko) | C형 간염 바이러스 감염의 새로운 치료법 | |
| US20090035273A1 (en) | Combination treatment method with interferon-tau | |
| HK1008811A (en) | Combination therapy for chronic hepatitis c infection | |
| JP5034944B2 (ja) | インターフェロン作用物質の活性増強剤 | |
| MXPA97008885A (en) | Use of ribavirin and interferon alpha for the treatment of hepatiti | |
| Pellicano et al. | Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection | |
| WO2008021536A2 (en) | Use of interferon tau for the manufacture of a medicament in combination with interferon-alpha or interferon-beta for reduction of their adverse effects | |
| KR20140007927A (ko) | C형 간염 바이러스 감염을 치료하기 위한 알리스포리비르 | |
| Simsek et al. | Treatment of Chronic Hepatitis C Infection with Interferon α-2 a in a Turkish Population | |
| JP2004155777A (ja) | Ｃ型慢性肝炎治療剤 | |
| Dunn et al. | Agents in Development for the Treatment of Hepatitis C: Summary and Table | |
| MXPA06001695A (en) | Method of treating viral infections |